Finasteride Tablet, Film Coated
Product Images NDC 63629-1585

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 63629-1585). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline ± 1 SE over a timeline from baseline to year 4. The graph compares two groups: Placebo and Finasteride, with placebo represented by circles and finasteride by squares. Data points for each group at baseline, year 1, year 2, year 3, and year 4 are included, with treatment groups showing decreasing symptom scores for Finasteride compared to Placebo.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

Line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' comparing Finasteride and Placebo groups over 48 months. The y-axis shows percent of patients (0-15%), and the x-axis shows observation time in months (0-48). The Finasteride group (solid line) shows lower cumulative surgery rates than the Placebo group (dashed line). Below the graph is a table listing cumulative event counts and number of patients at risk per year for both groups.*

FDA Label Image

Figure 4 Prostate Volume In A Long-term Efficacy And Safety Study (Finasteride Fig3)

A line graph displaying prostate volume changes over four years in a long-term efficacy and safety study. The y-axis shows mean percent change from baseline with error bars, while the x-axis indicates time points from baseline to year 4. Two groups are compared: placebo (circles) showing an increase, and finasteride (squares) showing a decrease in prostate volume. Sample sizes for both groups at each time point are listed below the graph.*

FDA Label Image

Figure 5 Cumulative Incidence Of A 4-point Rise In Aua Symptom Score By Treatment Group (Finasteride Fig4)

A line graph showing the cumulative incidence of a 4-point rise in AUA Symptom Score by treatment group over 5.5 years from randomization. The y-axis represents the percent with event, and four treatment groups are plotted: Placebo, Finasteride, Doxazosin, and Combination, with Placebo having the highest incidence and Combination the lowest.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride, shown as a detailed molecular diagram representing its steroid-like complex ring structure with functional groups attached.*

FDA Label Image

Label Image (Lbl636291585)

Finasteride Tablets USP 5 mg film-coated oral tablets packaging label. The label indicates a bottle containing 100 tablets, repackaged by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. It includes storage instructions, warnings against use by women or children, and a typical adult dosage statement.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.